EPARs human use - Privigen//human normal immunoglobulin (IVIg)

FICHA FARMACOLÓGICA de human normal immunoglobulin (IVIg). Contiene la Monografía en distintos idiomas (de la Comunidad Económica Europea), así como la discusión científica que sustenta su aprobación terapéutica. Para acceder a la monografía en idioma español, hacer doble clik en la sigla (es) en la fila que se sitúa más abajo del centro de la página oficial. Cerasale. JUNIO 06, 2009.-

abrir aquí:
EPARs for authorised medicinal products for human use - Privigen

Active Substance
human normal immunoglobulin (IVIg)
International Nonproprietary Name or Common Name
human normal immunoglobulin (IVIg)
Pharmaco-therapeutic Group
Immunoglobulins, normal human
ATC Code
J06BA02

Therapeutic Indication:
Replacement therapy in:
- Primary immunodeficiency (PID) syndromes such as:
- congenital agammaglobulinaemia and hypogammaglobulinaemia
- common variable immunodeficiency
- severe combined immunodeficiency
- Wiskott Aldrich syndrome
- Myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.
- Children with congenital AIDS and recurrent infections.

Immunomodulation:
- Immune thrombocytopenic purpura (ITP), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.
- Guillain-Barré syndrome.
- Kawasaki disease.

Allogeneic bone marrow transplantation.

Date of issue of Marketing Authorisation valid throughout the European Union
25 April 2008